MedTrace Logo

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

NCT06209606 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-12-17

No results posted yet for this study

Summary

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.

Conditions

Interventions

DRUG

Ruxolitinib Oral Tablet [Jakafi]

Ruxolitinib will be administered on days 1-28 of the treatment cycle.

DRUG

Lenalidomide

Lenalidomide will be administered on Days 1-21 of the treatment cycle.

DRUG

Methylprednisolone

Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.

Sponsors & Collaborators

Principal Investigators

  • James Berenson, MD · Oncotherapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-08
Primary Completion
2026-05-31
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06209606 on ClinicalTrials.gov